Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.
週六，波士頓科學公司（紐約證券交易所代碼：BSX）公佈了WATCHMAN FLX左心房附屬物閉合裝置（LAAC）的OPTION全球臨床試驗的三年主要終點結果。
The WATCHMAN implant device is about the size of a quarter and shaped like a parachute. It is implanted into the heart to close off the left atrial appendage, a blind pouch of heart tissue to prevent blood clots from forming and causing a stroke.
WATCHMAN 植入設備的大小約爲四分之一，形狀像降落傘。它被植入心臟以封閉左心房附屬物，這是一種心臟組織的盲袋，用於防止血塊形成並導致中風。
Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at the American Heart Association's Scientific Sessions 2024 and simultaneously published in "The New England Journal of Medicine."
該研究將該設備與一線口服抗凝劑（OAC）（包括直接口服抗凝劑（DOAC）（95％）和華法林（5％）進行了比較，以降低心臟消融後非瓣膜性心房顫動患者的中風風險，該研究的主要發現已在美國心臟協會的2024年科學會議上發表，並同時發表在《新英格蘭醫學雜誌》上。
Also Read: Why is Boston Scientific Stock Trading Lower On Wednesday?
另請閱讀：爲什麼波士頓科學股票週三交易價格走低？
The trial met the primary safety endpoint of non-procedural major bleeding or clinically relevant non-major bleeding at 36 months, with the WATCHMAN FLX device demonstrating superiority to OAC (8.5% vs.18.1%)
該試驗在36個月時達到了非手術性大出血或臨床相關非重度出血的主要安全終點，WATCHMAN FLX設備顯示出優於OAC（8.5％對18.1％）
It also met the primary efficacy endpoint of all-cause death, stroke, or systemic embolism at 36 months, with the data showing non-inferiority of the device to OAC (5.4% vs. 5.8%).
它還在36個月時達到了全因死亡、中風或系統性栓塞的主要療效終點，數據顯示該設備不遜於OAC（5.4％對5.8％）。
Additional findings included non-inferiority of the WATCHMAN FLX device for the combined secondary endpoint of procedural and non-procedural major bleeding at 36 months (3.9% vs. 5.0%).
其他發現包括WATCHMAN FLX設備在36個月時在手術和非手術性大出血的綜合次要終點方面沒有劣勢（3.9％對5.0％）。
The OPTION trial included 1,600 patients.
OPTION試驗包括1,600名患者。
In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure. The other nearly 40% of the device patients had the two procedures performed concomitantly, with the WATCHMAN FLX implant taking place after the ablation.
在試驗中，大約60％的設備患者在消融手術後的90-180天內植入了WATCHMAN FLX。其他近 40% 的設備患者同時接受了這兩項手術，WATCHMAN FLX 植入術是在消融後進行的。
In addition to the OPTION trial, the WATCHMAN technology is being evaluated against DOAC as first-line therapy in lower-risk patients within the CHAMPION-AF randomized trial.
除OPTION試驗外，還在CHAMPION-AF隨機試驗中對照DOAC作爲低風險患者的一線療法對WATCHMAN技術進行評估。
The latest-generation WATCHMAN FLX Pro LAAC Device was approved in the U.S. in 2023. It is similarly being studied in several clinical trials.
最新一代 WATCHMAN FLX Pro LAAC 設備於 2023 年在美國獲得批准。幾項臨床試驗也在對其進行類似的研究。
Price Action: BSX stock is up 4.36% at $90.79 at last check Monday.
價格走勢：週一最後一次檢查時，BSX股價上漲4.36％，至90.79美元。
- Netflix Scores Big: Beyoncé Set To Headline NFL Christmas Halftime Show
- Netflix 大獲全勝：碧昂斯將成爲 NFL 聖誕節半場秀的頭條新聞
Image: Shutterstock
圖片：Shutterstock
